Background: The presence of infective microorganisms in the bilio-pancreatic tract is believed to be important in both the onset and outcome of acute biliary pancreatitis. In this study ...

Biliary tract cancer is increasing in incidence and mortality across Europe, with more people under the age of 60 years old now impacted by the disease. However, despite this, knowledge about ...

“The IST complements our ongoing second-line Phase 2/3 study of tovecimig in patients with biliary tract cancer; importantly, we recently announced that tovecimig met the primary endpoint in our ...

MSD’s PD-1 inhibitor Keytruda has been approved by the FDA as a treatment for locally advanced unresectable or metastatic biliary tract cancer (BTC) in combination with chemotherapy, the first ...

Eisai has filed for approval in Japan for tasurgratinib, its small-molecule fibroblast growth factor (FGF) receptor inhibitor, as a treatment for biliary tract cancers with FGFR2 gene fusion ...

Topline data were announced from a phase 2/3 trial evaluating tovecimig in combination with paclitaxel in patients with unresectable advanced, metastatic or recurrent biliary tract cancers (BTC).

Biliary tract cancer is estimated to affect approximately 23,000 patients annually in the United States. The study enrolled 168 adult patients. All patients were dosed with 80 mg/m2 of paclitaxel ...

"We are thrilled to share these positive primary endpoint data from the COMPANION-002 study of tovecimig in patients with advanced biliary tract cancer," said Thomas Schuetz, MD, PhD, CEO of ...